Program, where he cared for patients undergoing stem cell transplants. Dr. Cagnoni earned his medical degree from University Buenos Aires School of Medicine, and he completed his fellowship
in Hematology and Oncology at the Mount Sinai Medical Center, New York and a fellowship in Stem Cell Transplantation at the University of Colorado Health Sciences Center. Dr. Cagnoni is a member of the Board of Directors for Fusion
Pharmaceuticals, Repertoire Immune Medicines, Synthekine and Tizona Therapeutics.
We believe Dr. Cagnonis broad operational
and transactional experience make him well qualified to serve as a member of our board of directors.
Luke Evnin, Ph.D., serves our
Chief Executive Officer. Dr. Evnin has more than 30 years of experience in healthcare investing, and is co-founder and Managing Director of MPM Capital. Dr. Evnin
co-founded MPM in 1997 with Ansbert Gadicke, M.D., and opened the San Francisco office in 1999. Dr. Evnins passion for discovering and advancing groundbreaking drug discovery companies inspires his
work and that of the MPM team, which has been the driving force behind building companies such as BioMarin Pharmaceutical, CoStim Pharmaceuticals (acquired by Novartis), Epizyme, Idenix Pharmaceuticals (acquired by Merck), Idun Pharmaceuticals
(acquired by Pfizer), Pacira Pharmaceuticals, Pharmasset (acquired by Gilead), Potenza Therapeutics (acquired by Astellas Pharma) and Radius Health. Dr. Evnin was the lead investor and has served on the boards of several of MPMs
investments including CoStim, Idun and Pacira. Over his career he has served on over 30 boards including nine public companies. Over the past seven years, as one key aspect of his MPM activities, Dr. Evnin has been a co-founder of seven MPM portfolio companies including Amphivena Therapeutics, Blade Therapeutics, Harpoon Therapeutics, Potenza Therapeutics, Maverick Therapeutics, Tizona Therapeutics and Werewolf Therapeutics. He
has contributed as an inventor to several of these companies as well as MPM portfolio company Oncorus where he currently serves on the Board of Directors.
In recognition of MPMs novel work to finance and build companies which may have a significant impact on cancer care and cures globally,
Dr. Evnin is a co-recipient of the 2017 Global Oncology Visionary Award. He has also devoted significant effort to working with the Scleroderma Research Foundation, serving as its Chairman since 2002.
Prior to co-founding MPM, he honed his skills as a venture capitalist at Accel Partners where he focused on emerging healthcare companies. Dr. Evnin advanced his technical training and launched his
interest in curing disease in the Department of Biochemistry at the University of California, San Francisco where he received his Ph.D., and his passion for drug discovery began at Princeton University where he received his A.B. in Molecular
Biology.
Todd Foley, M.B.A., serves as our President. Mr. Foley is an experienced biotech investor and executive and is a
Managing Director at MPM Capital. He currently serves as Chairman of Aktis Oncology and a board member of Chiasma (NASDAQ: CHMA), CODA Biotherapeutics, Entrada Therapeutics, Iconic Therapeutics, Repare Therapeutics (NASDAQ: RPTX), Rhythm
Pharmaceuticals (NASDAQ: RYTM), and Tetherex Pharmaceuticals, all MPM portfolio companies. Mr. Foleys successful exits include Semma Therapeutics, a potentially curative diabetes cell-therapy company founded by MPM and Doug Melton at
Harvard, which was acquired by Vertex for $950 million in 2019 in one of the largest ever preclinical M&A deals. He guided Selexys Pharmaceuticals, as the only institutional investor and director, to a successful acquisition by Novartis for
$665 million in 2016; Novartis launched the Selexys drug, Adakveo in late 2019 to treat sickle cell disease.
Mr. Foley has managed MPMs strategic investment relationship with Novartis, which committed $200 million to over a dozen
companies in the biotech and healthcare IT space under a variety of creative joint equity/strategic deal structures. Prior to joining MPM in 1999, Mr. Foleys career in the life science industry included business development at Genentech
(Roche) and management consulting with Arthur D. Little. He earned his M.B.A. from Harvard Business School and his B.S. in Chemistry from the Massachusetts Institute of Technology.
Ed Hurwitz, J.D., M.B.A., serves as our Chief Financial Officer. Mr. Hurwitz is an accomplished biotech executive and investor,
and is a Managing Director at MPM Capital. Mr. Hurwitz serves as Chairman of MPM portfolio companies BioIntervene and Rekindle Therapeutics and on the boards of Dyne Therapeutics (NASDAQ: DYN), Recode Therapeutics and Protego Biosciences, all
MPM portfolio companies.
Prior to MPM, he was founder and Managing Director of Precision BioVentures where he founded and seeded start-up biotechnology companies, including Viewpoint Therapeutics. As a Director at Alta Partners, he led 12 investments including Applied Genetic Technologies Corporation, Avid Radiopharmaceuticals (acquired by
Lilly), Calistoga Pharmaceuticals (acquired by Gilead), Cara Therapeutics, FoldRx Pharmaceuticals (acquired by Pfizer),
62